tlooto
Sign up
Medicine

Coopting Germline BRCA2 Mutation With an Available PARP Inhibitor to Manage Resistance to EGFR Targeted Therapy in EGFR-Mutated Lung Cancer: Combination of Olaparib With Osimertinib.

Hyunwoo Kwon, H. Viray, R. Gaudet, P. VanderLaan, Susumu Kobayashi, D. Rangachari, Daniel B. Costa

2026.2.1Clinical Lung Cancer

DOI: 10.1016/j.cllc.2026.02.005

Abstract

Abstract is not available.

Citation format

KWON, Hyunwoo, et al. Coopting germline BRCA2 mutation with an available PARP inhibitor to manage resistance to EGFR targeted therapy in EGFR-Mutated lung cancer: Combination of olaparib with osimertinib. Clinical Lung Cancer, 2026, 27 3(3): 12–16.